MiR-375 and miR-199a-5p promote cetuximab resistance in CRC patients by repressing the expression of PH domain and leucine-rich repeat protein phosphatase 1 (PHLPP1) and positively regulating AKT signaling pathway (51). This evidence concerns the gene AKT1 and colorectal carcinoma.